Immunomodulatory drugs combat MM by suppressing immune escape (25, 26) while proteasome inhibitors exert therapeutic effects through mechanisms such as inducing tumor cell apoptosis and inhibiting the NF-κB signaling pathway (27–29). The gene discussed is NFKB1; the disease is neoplasm.